2020 marks the 10th anniversary of our first call for projects! Learn about our researchers, their scientific advances and how some of their discoveries have been translated into applications for human health.
Decio Eizirik (WELBIO / ULB) et son équipe décrivent des signatures moléculaires similaires entre différentes maladies auto-immunes, identifiant des voies clés qui pourraient être ciblées pour la thérapie.
Cédric Blanpain (WELBIO – ULB) and his team identify the functions of FAT1, one of the most frequently mutated cancer gene drivers, uncovering that FAT1 mutations promote invasive features, metastasis and resistance to commonly used anti-cancer drugs
Director of the Laboratory of Stem Cells and Cancer (ULB), WELBIO investigator, Pr. Cédric Blanpain is awarded the Francqui-Collen Prize for his fundamental research in cancer and stem cells biology.
Kaneka and its Walloon subsidiary, Kaneka Eurogentec S.A., enter into a partnership with Pr Jean-François Collet's laboratory (WELBIO UCLouvain) by funding a new joint research group at the Duve Institute.
These results from the team of Jean-Luc Balligand (WELBIO – IREC - UCLouvain) pave the way for the development of more potent molecules to block aquaporin and treat heart failure more efficiently.
This jammer prevents proper regulation of sugar, causing insulin resistance in people with diabetes. Patrice Cani (UCLouvain) and Claude Knauf (INSERM) also discover that a lipid produced by our body helps preventing this dysfunction.
François Fuks (WELBIO – ULB) and his colleagues show the key role of a chemically modified RNA letter, hydroxymethylcytosine (hmC), during the differentiation of embryonic stem cells.
Sophie Lucas (WELBIO – UCLouvain) and her team neutralize a molecule that blocks immune responses against cancer. This novel form of immunotherapy induces tumor regressions by strongly increasing the efficacy of another well-known immunotherapy.
The Human Molecular Genetics laboratory headed by Miikka Vikkula (WELBIO – UCLouvain) identified a gene responsible for primary lymphedema, a discovery essential for proper diagnosis and opening possibilities for the development of treatments.
Researchers led by Cédric Blanpain (WELBIO – ULB) identify for the first time the mechanisms by which cell-cell communication control the fate of mammary and prostate stem cells.